Lens Lab

Myopia-Control Lenses, Explained: Stellest, MiYOSMART iQ & MyoActive

By 4 Eyes Club · October 2026 · 9 min read

This is educational information, not medical advice. Talk to your eye doctor about what's right for you or your child.

If your kid's glasses prescription keeps getting stronger every year, you've probably heard the phrase "myopia control" at some point — maybe from your optometrist, maybe from another parent. A new generation of spectacle lenses is designed to slow down how fast nearsightedness progresses in children. Here's what the three big ones are, what the trial evidence actually shows, and what questions to bring to your eye doctor.

First: what myopia progression is, and why it matters

Myopia (nearsightedness) usually develops in childhood and often gets worse as kids grow. The eyeball grows slightly too long, so light focuses in front of the retina instead of on it. Each stronger prescription isn't just a number on a lens order — it reflects the eye elongating further. And higher degrees of myopia later in life are associated with higher risk of serious eye conditions like retinal detachment, glaucoma, and myopic maculopathy.

That's the logic behind myopia control: intervene during childhood, slow the eye's elongation, and reduce the final prescription. Standard single-vision glasses correct vision perfectly well, but they don't try to slow progression. Myopia-control lenses do both — they correct vision and incorporate optical designs intended to slow the eye's growth.

The market context matters here too: kids are the fastest-growing segment in eyewear, at roughly 12% annual growth on the back of the myopia story, and Asia-Pacific is the fastest-growing region, driven significantly by school-age myopia in China (~7.5% CAGR). This is a real, large-scale health trend, not a niche concern.

How these lenses work (the non-jargon version)

Without going into a physics lecture: the leading theory is that certain patterns of defocused light hitting the peripheral retina signal the eye to slow its growth. Myopia-control spectacle lenses embed special optical zones — tiny lenslets, rings, or segments — alongside the central correction zone, creating that defocus pattern while your child sees clearly through the middle. The child wears them like normal glasses. No drops, no contacts, no nighttime devices.

That's the appeal in one sentence: it looks and feels like regular glasses. For kids who can't or won't manage contact lenses, and parents uneasy about daily eye drops, spectacle-based myopia control has an obvious comfort advantage. Whether the evidence supports that comfort is the right question — so let's look at it product by product.

Essilor Stellest: the FDA-cleared one

Stellest, from Essilor (part of EssilorLuxottica), is the headline name in this space for a specific reason: in September 2025, it became the first FDA-cleared myopia-control spectacle lens. FDA clearance (technically an authorization) is a regulatory milestone, not a guarantee of results for any individual child, but it does mean the agency reviewed the evidence and found it supports the claims made for the lens.

The headline trial numbers, from a two-year US trial: 71% less myopia progression and 53% less axial elongation compared to standard single-vision lenses. Read those carefully — they're averages across trial participants, and "less progression" doesn't mean "no progression." Some children in the trial still progressed. But as group-level evidence, it's the strongest dataset in the category, and it's why Stellest is the name your optometrist is most likely to mention first.

Stellest uses Essilor's H.A.L.T. (Highly Aspherical Lenslet Target) technology — a constellation of aspherical lenslets in the periphery of the lens. It's been on the market internationally since 2020, so there's also longer-term real-world data beyond the US trial, which is worth asking your eye doctor about.

Hoya MiYOSMART: the most widely used one

Hoya's MiYOSMART is the veteran of the three in terms of market presence: 15M+ lenses sold in 50+ countries since 2018, and it's been reimbursed in France since July 2025 — a meaningful signal that a national health system considers the evidence strong enough to pay for it.

The 2026 development: Hoya's MiYOSMART iQ, with trial data presented at ARVO 2026 in Denver. The headline: 9 out of 10 children showed halted progression at 12 months. As with Stellest, read it as a trial result — "halted progression" at the one-year mark, in that study population. It's genuinely strong data, and it's why the iQ launch is rolling out across Canada, China, Spain, Australia, and New Zealand in 2026.

One important geography note: MiYOSMART iQ is not available in the US as of our research. Availability of these lenses varies significantly by country — a theme that repeats across the category and a practical question to ask early: which of these products can I actually get here?

MiYOSMART uses D.I.M.S. (Defocus Incorporated Multiple Segments) technology — a honeycomb of small segments creating myopic defocus. The original version has eight years of real-world use behind it, which is the longest track record in the category.

ZEISS MyoActive: the newest one

ZEISS MyoActive launched October 1, 2026 — this month — in Canada. It's the newcomer, and its angle is different: it's built on what ZEISS calls "Dynamic Signal Theory," implemented through M.O.V.E. technology. Without endorsing the branding, the core idea is a different approach to how the defocus signal is structured across the lens.

The trial numbers ZEISS reports: 0.60 diopters less progression compared to standard lenses, and 98% of children adapted within a week. The adaptation figure matters more than it looks — these lenses ask kids' visual systems to process a different peripheral image, and fast adaptation means fewer complaints, fewer returns, and more consistent wear. Consistent wear is the whole game: a myopia-control lens sitting in a drawer controls nothing.

As the newest entrant, MyoActive has the shortest track record and the smallest long-term dataset. That doesn't disqualify it — it means the evidence base is younger, and it's fair to ask your eye doctor how they weigh that against the longer histories of Stellest and MiYOSMART.

How to read the evidence like a skeptic

All three products report impressive-sounding numbers. Here's the framework we'd use to evaluate any myopia-control claim, from any brand:

• Absolute vs. relative numbers. "71% less progression" is relative. Ask: 71% of what baseline? A big relative reduction on a small baseline is still good news, but absolute diopters tell you the real-world size of the effect.
• Time horizon. Twelve-month data (MiYOSMART iQ) and two-year data (Stellest) answer different questions. Myopia management is a multi-year project; longer follow-up is more convincing. Ask what the longest published follow-up is for any option you're considering.
• Axial length, not just prescription. Axial elongation — the physical lengthening of the eye — is the more meaningful outcome than the prescription number, because it's what drives long-term risk. Stellest's trial reported both (71% less progression, 53% less axial elongation). Prefer evidence that reports both.
• Who was in the trial. Age range, baseline prescription, ethnicity, geography. Results in one population don't automatically transfer to another — this matters especially given myopia's different prevalence patterns across regions.
• Regulatory status where you live. FDA clearance (Stellest, US), reimbursement (MiYOSMART, France), new launch (MyoActive, Canada). Regulatory milestones are evidence that someone rigorous reviewed the data — they're not a verdict that it's the right choice for your child.

What to ask your eye doctor

This is the part where we get practical. Bring this list to the appointment:

1. Is my child's myopia progressing fast enough that intervention is worth discussing? (Not every mild, stable case needs it.)
2. Which myopia-control options are available to us here — spectacle lenses, and what else?
3. What does the evidence look like for each option, in absolute terms?
4. What are the tradeoffs — cost, replacement frequency as prescriptions change, adaptation period?
5. How will we measure whether it's working — and on what timeline do we reassess?
6. What else matters alongside lenses — outdoor time, screen habits, follow-up schedule?

That last question is deliberate. No lens replaces the fundamentals: regular eye exams, time outdoors (which has its own evidence base for myopia), and monitoring. Myopia-control lenses are a tool, not a cure — the honest framing, and the one your eye doctor will recognize.

The bottom line, without the sales pitch

Myopia-control spectacle lenses are the most genuinely exciting lens story in years — a real evidence-based category, with an FDA-cleared product, a 15-million-lens veteran, and a brand-new ZEISS entrant landing this month. The trial data is legitimately strong at the group level. The honest caveats are equally real: results are averages, not guarantees; availability is geographic; and the longest datasets still span years, not decades.

Our position: this is a conversation to have with your eye doctor, armed with the right questions — not a product to pick from a blog post. We wrote this so you can walk into that conversation already fluent. That's the job.

This is educational information, not medical advice. Talk to your eye doctor about what's right for you or your child.